Jubilant Energy labels Indian discovery as commercial
Jubilant Energy, the AIM-listed hydrocarbon group, has achieved an important milestone at its Tripura project in India with a 'Declaration of Commerciality' (DoC) having been submitted for the Kathalchari gas discovery.
Jubilant Energy, the AIM-listed hydrocarbon group, has achieved an important milestone at its Tripura project in India with a 'Declaration of Commerciality' (DoC) having been submitted for the Kathalchari gas discovery.
The company, which owns a 20% interest in Tripura, is now awaiting approval from the Directorate General of Hydrocarbons, after which it will submit a field development plan to the government.
Tripura is located in the fold belt area of the Assam-Arakan Basin in north-eastern India, the country's oldest producing basin with some of its largest producing fields. While Jubilant is the operator, GAIL India holds the remaining 80% stake in the block.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The Kathalchari discovery was first made in the Tripura block in late 2009 with the phase-1 exploration well Kathalchari-1 (KL-1).
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge